NCT00838890 - A Study of BMS-863233 in Patients With Hematologic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Refractory Hematologic Cancer

Interventions

DRUG

Cdc7-inhibitor (BMS-863233)

Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months

DRUG

Cdc7-inhibitor (BMS-863233)

Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months

Trial Locations (4)

Roswell Park, Buffalo

University Of Miami, Miami

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Massachusetts General Hospital, Boston